Levosimendan
Cross-source consensus on Levosimendan from 1 sources and 5 claims.
1 sources · 5 claims
Uses
How it works
Benefits
Highlighted claims
- Levosimendan is a calcium sensitiser and vasodilator approved for acute heart failure treatment. — Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial
- Levosimendan improves calcium sensitivity of force generation in cardiac muscle by modulating the troponin complex. — Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial
- The WEANLESS hypothesis is that levosimendan will shorten weaning by restoring diaphragm contractility. — Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial
- Prior research found that levosimendan improved calcium sensitivity in human diaphragm fibres. — Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial
- In critically ill ventilated patients, levosimendan increased ventilation measures, reduced arterial carbon dioxide, and caused no serious adverse events in a prior study. — Weaning from invasive ventilation with levosimendan (WEANLESS): study protocol for a multicentre randomised clinical trial